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A B S T R A C T   
Organic anion-transporting polypeptide 2B1 (OATP2B1) is a multispecific transporter mediating the cellular 
uptake of steroids and numerous drugs. OATP2B1 is abundantly expressed in the intestine and is also present in 
various tumors. Increased steroid hormone uptake by OATP2B1 has been suggested to promote progression of 
hormone dependent tumors. 13α-estrones are effective inhibitors of endogenous estrogen formation and are 
potential candidates to inhibit proliferation of hormone dependent cancers. Recently, we have identified a va-
riety of 13α/β-estrone-based inhibitors of OATP2B1. However, the nature of this interaction, whether these 
inhibitors are potential transported substrates of OATP2B1 and hence may be enriched in OATP2B1- 
overexpressing cells, has not yet been investigated. In the current study we explored the antiproliferative ef-
fect of the most effective OATP2B1 inhibitor 13α/β-estrones in control and OATP2B1-overexpressing A431 
carcinoma cells. We found an increased antiproliferative effect of 3-O-benzyl 13α/β-estrones in both mock 
transfected and OATP2B1-overexpressing cells. However, C-2 halogenated 13α-estrones had a selective 
OATP2B1-mediated cell growth inhibitory effect. In order to demonstrate that increased sensitization can be 
attributed to OATP2B1-mediated cellular uptake, tritium labeled 2-bromo-13α-estrone was synthesized for direct 
transport measurements. These experiments revealed increased accumulation of [3H]2-bromo-13α-estrone due to 
OATP2B1 function. Our results indicate that C-2 halogenated 13α-estrones are good candidates in the design of 
anti-cancer drugs targeting OATP2B1.   
1. Introduction 
Organic anion-transporting polypeptides (OATPs) are membrane 
proteins mediating the cellular uptake of various endogenous and 
exogenous organic compounds in a Na+ and ATP independent manner 
(Hagenbuch and Stieger, 2013). The known 11 human OATPs vary in 
their tissue distribution and substrate specificity. Some members of the 
OATP family are expressed ubiquitously in the human body (Konig et al., 
2000; Roth et al., 2012), while others possess a tissue specific expres-
sion, like OATPs, 1B1 and 1B3, expressed exclusively in hepatocytes 
(Konig et al., 2000). OATPs, 1A2, 1B1, 1B3 and 2B1 are multispecific 
transporters recognizing a plethora of organic compounds, while for e. 
g., OATP1C1, a thyroid transporter, has a more limited substrate 
recognition pattern (Kovacsics et al., 2017; Pizzagalli et al., 2002) at 
least based on the available research data. Steroids, like bile acids and 
steroid hormones are common OATP substrates. OATPs, 1A2, 1B1, 2B1 
and 4A1 are key participants in the cellular uptake of estrone-3-sulfate 
(E1S) and dehydroepiadrosterone-sulfate (DHEAS) and hence these 
OATPs are important in the maintenance of steroid hormone homeo-
stasis (Rizner et al., 2017). On the other hand, altered expression of 
OATPs in tumors was documented by numerous studies (Buxhofer- 
Ausch et al., 2013; Thakkar et al., 2015). It has been proposed that 
elevated uptake of nutrients and hormones by OATPs provides a selec-
tive advantage of tumor cells over their healthy counterparts (Buxhofer- 
Ausch et al., 2013). For example, overexpression of OATPs, 1A2, 1B3 
and 2B1 results in enhanced uptake of E1S and DHEAS and consequently 
issue in an increased survival of breast cancer cells in vitro (Arakawa 
et al., 2012; Matsumoto et al., 2015; Nozawa et al., 2004). Moreover, in 
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vivo data from prostate cancer patients also underline that OATP 
expression promotes tumor progression. Enhanced testosterone uptake 
by OATP1B3, or DHEAS by OATP2B1 stimulates prostate cancer pro-
gression (Hamada et al., 2008; Wright et al., 2011). Therefore, inhibi-
tion of the uptake of hormones or hormone precursors by OATPs may be 
a potential strategy in the treatment of hormone dependent cancers. 
On the other hand, multispecific OATPs also recognize various 
medicines, encompassing chemotherapeutics. Hence, they can poten-
tially be targeted to increase intratumor accumulation of chemothera-
peutic agents. For instance, OATPs, 1B1 and 1B3 transport atrasentan, 
sorafenib-glucuronide, SN-38 (the active metabolite of irinotecan), 
docetaxel, methotrexate, paclitaxel, and doxorubicin (Durmus et al., 
2016). Additionally, OATP2B1, overexpressed in several cancers, 
including tumors of the breast, colon, bone and gliomas (Kovacsics et al., 
2017), promotes the intracellular accumulation of abiraterone (Mosta-
ghel et al., 2017), erlotinib (Bauer et al., 2018), etoposide (Fahrmayr 
et al., 2012), teniposide (Schafer et al., 2018) and SN-38 (Fujita et al., 
2016). OATP2B1 has been shown to sensitize tumor cells to various 
chemotherapeutics (e.g.: tamoxifen, cytarabine) (Windt et al., 2019). 
Inhibition of local estradiol synthesis through the inhibition of the aro-
matase or steroid-sulfatase (STS) pathways (e.g. by Exemestane or Irosustat, 
respectively (Gupta et al., 2013; Sang et al., 2018)) is a medical strategy to 
treat hormone dependent breast cancer in postmenopausal women. 
Recently, various 13α-estrone-derivatives have been developed that inhibit 
another key enzyme of local estradiol synthesis, 17β-hydroxysteroid dehy-
drogenase 1 (HSD1) (Ayan et al., 2011; Bacsa et al., 2015). 13α-estrone is 
the epimer of the natural 13ß-estrone that, due to a configurational change, 
cannot bind to the estrogen receptor and lacks hormonal activity (Ayan 
et al., 2011; Yaremenko and Khvat, 1994; Schonecker et al., 2000). More-
over, various 13α-estrones have been shown to inhibit the steroid trans-
porter OATP2B1 as well (Jojart et al., 2018; Jójárt et al., 2021). Therefore, 
these derivatives are a promising novel, dual-target tool for the treatment of 
hormone sensitive cancers. Furthermore, if 13α-estrones were enriched in 
tumors by the function of OATP2B1 it could also potentially enhance their 
efficacy. Therefore, in the current study we investigated the antiproliferative 
effect of a set of previously identified 13α-estrone derivative OATP2B1 in-
hibitors to identify potential OATP2B1-transported substrates. 
2. Materials and methods 
2.1. Materials 
If not stated otherwise materials were purchased from Sigma Aldrich, 
Merck (St. Louis, MO, US). The investigated steroids were synthetized as 
described elsewhere (Bacsa et al., 2018; Jojart et al., 2018; Jójárt et al., 
2021). 
Tritium labeling was carried out in a self-designed vacuum manifold 
(Schafer et al., 2015), radioactivity was measured with a Packard Tri- 
Carb 2100 TR liquid scintillation analyzer using Hionic-Fluor scintilla-
tion cocktail of PerkinElmer. Radio-HPLC was performed on a Jasco 
HPLC system equipped with a Packard Radiomatic 505 TR Flow Scin-
tillation Analyzer. 
2.2. Synthesis of 2-bromo-13α-estrone 
2-Bromo- and 2,4-dibromo-13α-estrone were synthesized as 
described elsewhere (Bacsa et al., 2018). 
2.3. Preparation of [3H]2-bromo-13α-estrone ([3H]2_2Br) 
4.3 mg of 2,4-dibromo-13α-estrone (10 μmol) was dissolved in 0.6 mL of 
EtOAc in the presence of 5 mg of Pd/C (10% Pd) catalyst and 3 μL of 
triethylamine (21 μmol). The reaction mixture was degassed prior to tritium 
reduction by two freeze-thaw cycles, and then it was stirred under 0.18 bar 
of tritium gas for 2 h at rt. The excess tritium gas was then absorbed onto 
pyrophoric uranium and the catalyst was filtered off with a syringe filter. 
The filtrate was evaporated in vacuo and the labile tritium was removed by 
repeated evaporations from EtOH solution. Finally, 10.6 GBq of [3H]13α- 
estrone (2) was isolated as a white solid that was immediately used for the 
next step. 450 MBq of [3H]13α-estrone (2) was dissolved in 200 μL of 
dichloromethane and 28 μL of 1,3-dibromo-5,5-dimethylhydantoin dis-
solved in dichloromethane (5 mg/mL, 0.45 μmol) was added. The solution 
was stirred for 15 min then it was evaporated and the resulting solid was 
dissolved in tetrahydrofuran. HPLC purification resulted in 28 MBq of [3H] 
2_2Br. The specific activity was determined by using an HPLC peak area 
calibration curve recorded with 2-bromo-13α-estrone (2_2Br) and it was 
found to be 555 MBq/mmol. The tritium labeled [3H]2-bromo-13α-estrone 
([3H]2_2Br) was dissolved in EtOH (37 MBq/mL) and stored in liquid 
nitrogen. 
2.4. Generation and maintenance of the cell lines 
The A431 (human epidermoid carcinoma) cell line was purchased 
from ATCC. OATP2B1 and mock transfected A431 cell lines were 
generated as described previously (Patik et al., 2018). To generate cells 
with a fluorescent marker (green fluorescent protein, GFP or mCherry), 
A431 mock or A431-OATP2B1 cells were transduced with lentiviral 
supernatants produced with pRRL-EF1-mCherry or pRRL-EF1-eGFP 
expression plasmids (Windt et al., 2019). Cells were cultured in 
DMEM (Gibco, Thermo Fischer Scientific (Waltham, MA, US)) supple-
mented with 2 mM L-glutamine, 100 U/mL penicillin and 100 μg/mL 
streptomycin and 10% fetal calf serum at 37 ◦C with 5% CO2 and 95% 
humidity. 
2.5. Detection of OATP2B1 expression by Western blot 
OATP2B1 expression in the cell lines was confirmed by Western blot 
as previously described in (Patik et al., 2018). Shortly, whole cell lysate 
of the OATP2B1 and mock transfected cell lines were separated on 7.5% 
SDS-PAGE gels and proteins were transferred onto PVDF membranes. 
The presence of OATP2B1 was detected by an anti-OATP2B1 antibody (a 
kind gift of Dr. Bruno Stieger, Department of Clinical Pharmacology and 
Toxicology, University Hospital, 8091 Zurich, Switzerland (Kullak- 
Ublick et al., 2001) with an epitope of: LLVSGPGKKPEDSRV). As a 
secondary antibody 20,000 × diluted HRP-conjugated anti-rabbit anti-
body (Jackson ImmunoResearch, Suffolk, UK) was used. Antibody raised 
against ß-actin was applied as an internal control (anti-ß-actin antibody 
(A1978, Sigma)) and in this case a HRP-conjugated anti-mouse sec-
ondary antibody was used (Jackson ImmunoResearch, Suffolk, UK) in 
20,000 × dilution. Luminescence was detected by Luminor Enhancer 
Solution kit by Thermo Fisher Scientific (Waltham, MA, US). 
2.6. Functional measurements 
OATP2B1 expression was regularly checked by Zombie Violet (ZV, 
BioLegend®, San Diego, CA, US) uptake by flow cytometry (Patik et al., 
2018). A431-OATP2B1 and mock transfected cells were collected after 
0.1% trypsin treatment. The cells were washed with 1 mL uptake buffer 
(125 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM KH2PO4, 12 mM 
MgSO4, 25 mM MES, and 5.6 mM glucose, with the pH adjusted to 5.5 
using 1 N NaOH). 5 × 105 cells were incubated with ZV (0.4 μL ZV/5 ×
105 cells) for 15 min at 37 ◦C in a final volume of 100 μL. The reaction 
was stopped by adding 500 μL ice cold phosphate-buffered saline (PBS) 
and until the flow cytometry analysis the cells were kept on ice. The 
fluorescence of 10,000 living cells was determined by Attune NxT Flow 
Cytometer (Invitrogen, Carlsbad, CA). 
2.7. Fluorescence-based measurement of cell proliferation 
To measure the antiproliferative effect of the compounds, a 
fluorescence-based cell proliferation assay was performed as published 
in (Windt et al., 2019). The number of the fluorophore-labeled cells 
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(A431-mock-GFP and A431-OATP2B1-mCherry) is traceable over the 
incubation time, as the fluorescence is proportional with the number of 
the cells. 
Cells were seeded in a density of 5 × 103 cells/well on 96-well plates 
in 100 μL in DMEM supplemented with 2 mM L-glutamine, 100 U/mL 
penicillin and 100 μg/mL streptomycin and 10% fetal calf serum. After 
16–24 h the steroids diluted in 100 μL DMEM (0–50 or 0–100 μM final 
concentration) were added to the cells. As a control, 10 μM PZ-08 (3-N- 
benzyltriazolylmethyl-13α-estrone) was applied, previously shown to 
inhibit growth of A431 cells by 100% (Szabo et al., 2016b). The cells 
were cultured for 120 h at 37 ◦C with 5% CO2 after which cellular 
fluorescence was recorded by a Perkin Elmer Enspire microplate reader 
(GFP: ex/em 485/510 nm; mCherry: ex/em 585/610 nm) by scanning 
the plate at a resolution of five points per well. Cell number was 
calculated based on the fluorescence values measured in non-treated 
(100%) or PZ-08-treated (0%) wells. Experiments were repeated in at 
least 3 biological replicates with 3 parallels in each. Mean ± SD values 
are shown. 
2.8. Measurement of intracellular accumulation of 2_2Br 
A431 mock control and A431-OATP2B1 cells (106 cells/sample) 
were incubated in the presence of 0.135 μM [3H]2_2Br in a final con-
centration of 1 μM (or higher, see below) in 100 μL uptake buffer pH 5.5 
for 10 min at 37 ◦C (or on ice, see Figure 8). The reaction was stopped by 
the addition of 1 mL ice-cold PBS and the cells were centrifuged at 300g. 
The cell pellet was collected in 100 μL PBS and pipetted into 1 mL Opti- 
Fluor (Perkin Elmer, Waltham, MA, US). Radioactivity was measured in 
a Wallac Liquid Scintillation Counter. Experiments were repeated three 
times. 
Concentration dependent uptake was determined as described above 
with the exception that increasing concentrations of [3H]2_2Br (1–100 
μM) were applied for 5 min. For specific inhibition of OATP2B1, the cells 
were preincubated for 5 min in the presence of 20 μM bromo-
sulfophtalein in uptake buffer pH 5.5. After 5 min 1 μM [3H]2_2Br was 
added and the cells were further incubated for 10 min at 37 ◦C. Exper-
iments were repeated in at least 3 biological replicates in which cells 
derived from different passages with 3 technical parallels. 
2.9. Data analysis 
All data are presented by calculating the mean ± SD obtained from at 
least three independent measurements, with 3 technical replicates in 
each individual experiment. The IC50 values were determined by 
sigmoidal curve fitting using the GraphPad Prism software (version 6 for 
Windows, GraphPad Software, San Diego, California, US). For statistical 
analyses unpaired Student’s t-test was performed and the p value for 
statistical significance was set at *p < 0.05, **p < 0.01 or ***p < 0.001, 
****p < 0.0001. 
3. Results 
3.1. Enhanced antiproliferative effect of 2-halogenated 13α-estrones on 
cells overexpressing OATP2B1 
In our earlier studies we identified a series of 13α- and 13β-estrone 
derivatives that effectively inhibit the transport function of OATP2B1 
(Jojart et al., 2018; Laczko-Rigo et al., 2020; Jójárt et al., 2021). How-
ever, the nature of these interactions, whether these compounds are 
inhibitors or substrates of OATP2B1 was not investigated. Therefore, in 
the current study estrones with high affinity to OATP2B1 (IC50 ≤ 2 μM, 
see Figs. 1 and 2, and Table 1) were further investigated in an in vitro 
cell proliferation assay. In addition, as controls, in the case of haloge-
nated 13α-estrones the less effective OATP2B1 inhibitor 4-C haloge-
nated stereoisomers (2_4 series, see Table 1) were also tested. 
We hypothesized that transported toxic or cytostatic substrates of 
OATP2B1, due to their increased uptake by OATP2B1, will result in 
increased antiproliferative effect in cells expressing OATP2B1 (Windt 
et al., 2019). For this aim, we used the A431 cell line overexpressing 
OATP2B1, generated earlier in our laboratory. A431-OATP2B1 is an 
ideal tool for microplate based functional measurements (Patik et al., 
2018) including that of measuring cytotoxicity (Windt et al., 2019). In 
addition, it has been shown earlier that A431 cells are sensitive to 
certain 13α-estrone derivatives (Szabo et al., 2016b). In our study cell 
growth was followed by measuring the fluorescence of the protein used 
to tag the cells, GFP for mock transfected cells and mCherry for cells 
containing OATP2B1. We showed previously that fluorescence of GFP or 
mCherry is proportional to the cell number in the range of 5000–40,000 
cells, and therefore this simple method can be used to monitor cell 
growth or death without the need of the addition of cell viability re-
agents (Windt et al., 2019). Expression and function of OATP2B1 was 
confirmed and regularly checked in the A431-OATP2B1-mCherry cell 
line (Fig. 3). 
We found various degrees of cell proliferation inhibition of the 
OATP2B1 inhibitor 13α- and 13β-estrones. Estrone (1) had no significant 
antiproliferative effect on A431 cells, at least in the concentration range 
applied (Fig. 4). Similarly, 13α-estrone (2) and 3-O-methyl-13α-estrone 
(2b) had no effect on cell growth. However, 3-O-benzyl-13α-estrone 
(2a) exerted a well-measurable antiproliferative effect with an IC50 of 
10.36 μM (Fig. 4 and Table 1). 
We have demonstrated earlier that modification of the 13α- or 3β- 
estrone on C-2 or C-4 with diethylphosphite enhances its OATP2B1 
inhibitory action (Jojart et al., 2018; Jójárt et al., 2021). Here we found 
that C-2 or C-4 diethylphosphonate modification of 2a did not further 
increase cell growth inhibition as the IC50 values of 2- and 4- dieth-
ylphosphonates (15.91 μM and 10.52 μM, respectively) were unaltered 
Fig. 1. Selected 13β-estrone-based high affinity OATP2B1 inhibitor (1a_2P).  
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compared to 2a (Figs. 4 and 5 and Table 2). Similarly, 2- and 4-diethyl-
phosphonate variants of 2 (2_2P and 2_4P) and the 2- diethylphospho-
nated version of 3-O-methyl-13α-estrone (2b_2P) were found to have no 
major effect on cell growth. 
On the other hand, 3-O-benzyl-13α- and 13ß-derivatives (2a series 
and 1a_2P) resulted in significantly increased cell growth inhibition 
with IC50 values of around 10 μM (Fig. 5 and Table 2). However, in spite 
of their high affinity inhibition of OATP2B1 function, none of these 
compounds showed increased cell growth inhibition in A431-OATP2B1 
cells as compared to the mock-transfected controls. 
Similarly to the diethylphosphonated derivatives, the halogen 
substituted derivatives of 2 (2_2I, 2_2Br, 2_2Cl, 2_4Br or 2_4Cl) had no 
or only marginal (2_2I or 2_4I) effect on mock-transfected cells. How-
ever, the C-2 halogenated compounds showed increased cell growth 
inhibition (see Fig. 6 and Table 2) in cells overexpressing OATP2B1. The 
selective cell growth inhibition of C-2 halogenated 13α-estrones in 
OATP2B1-overexpressing cells can be interpreted as the result of cellular 
enrichment of these compounds by OATP2B1. Indeed, we found that 
inhibiting OATP2B1 function with the OATP-specific inhibitor bromo-
sulfophthalein (BSP) could partially block the effect of 2_2Br in A431- 
OATP2B1 cells (Supplementary Fig. S2A). 
3.2. Synthesis and tritium labeling of 2_2Br 
In order to investigate the possible OATP2B1-mediated transport of 
the most selective compound (with a 4-fold selectivity ratio, Table 2), 
radioactive labeling of 2-bromo-13α-estrone (2_2Br) was performed. 
Tritium labeling was carried out by catalytic dehalogenation of the bis- 
brominated compound 2,4-dibromo-13α-estrone in the presence of 
tritium gas followed by mono-bromination of [3H]1 at the C-2 position. 
The regioselective bromination cannot be achieved under various con-
ditions, and thus, a mixture of brominated compounds was obtained. 
Next, an HPLC method was developed for the separation of the com-
pounds [3H]2_2Br, [3H]2_4Br and the bis-brominated 2_2/4Br. The 
bromination of [3H]1 was performed in the presence of DDH with an 
optimal yield of [3H]2_2Br that was isolated by HPLC separation (Sup-
plementary Fig. S1). 
3.3. OATP2B1-mediated accumulation of [3H]-2-bromo-13α-estrone 
([3H]2_2Br) 
Cellular accumulation of [3H]2_2Br was measured in A431- 
OATP2B1 and mock control cells. We found that OATP2B1- 
overexpressing A431 cells accumulated twice more [3H]2_2Br than 
Fig. 2. Selected 13α-estrone-based high affinity OATP2B1 inhibitors.  
Table 1 
Inhibitory effect of the investigated compounds.  
Name IC50 ± SD (μM) Name IC50 ± SD (μM) 
1 2.06 2b >50 
± 0.043  
1a_2Pa 0.041 2_2Pb 2.8 
± 0.02 ±1.5 
2bb 3.4 2_4Pb 1.4 
± 0.3 ± 0.2 
2b_2Pb 1.8 2_2Ic 1.52 
± 0.3 ±0.01 
2b_4Pb 2.8 2_4Ic 6.63 
± 1.5 ±0.01 
2ab 1.7 2_2Brc 0.54 
± 0.9 ±0.02 
2a_2Pb 0.2 2_4Brc 10.8 
± 0.02 ±0.02 
2a_4Pb 0.3 2_2Clc 2.11 
± 0.02 ±0.02   
2_4Clc >50 
Inhibitory effect of the compounds was described earlier, with the exception of 
compound 1, a: (Jójárt et al., 2021), b: (Jojart et al., 2018), c: (Laczko-Rigo et al., 
2020). Compounds were tested on A431-OATP2B1 cells in a transport assay 
using CascadeBlue hydrazide as test substrate. IC50 values were determined by 
nonlinear regression analysis fitted to the data points by GraphPad Prism soft-
ware. Bold indicates compound names, italics is for SD values. 
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the control A431 cells (Fig. 8A). The concentration dependence of the 
cellular uptake of [3H]2_2Br in the range of 1–100 μM (at both pH 5.5 
(Fig. 8B) and pH 7.4 (Supplementary Fig. S3)) indicated a transporter 
mediated uptake mechanism that was further confirmed by the signifi-
cantly decreased transport in the presence of the OATP-specific inhibitor 
bromosulfophthalein, and by the lack of transport at 4 ◦C (Fig. 8C). 
4. Discussion 
OATP2B1 is a plasma membrane protein mediating intestinal and 
hepatic uptake of its substrates. On the other hand, OATP2B1 is also 
overexpressed in tumors of the colon, bone, breasts and gliomas 
(Kovacsics et al., 2017). Since OATP2B1 is a multispecific transporter 
recognizing a large set of chemically diverse compounds, including 
various drugs, one anti-tumor strategy could be to exploit its activity to 
increase intra-tumor concentrations of its substrate chemotherapeutics. 
Indeed, we have recently shown that OATP2B1 can sensitize the cells 
toward chemotherapeutics (Windt et al., 2019). 
Synthetic steroids, e.g. the estrogen receptor degrader Fulvestrant 
(Lee et al., 2017) and the aromatase inhibitor Exemestane (Van Asten 
et al., 2014) are frequently administered for hormone receptor positive 
breast cancers. However, steroid-based compounds face the challenge of 
lacking estrogenic activity. 13α-estrone derivatives are good candidates 
for anticancer treatment, since they have no hormonal activity, but 
interfere with local estrogen synthesis by inhibiting the STS and/or 
HSD1 enzymes. Indeed, several 13α-estrone derivatives were identified 
as antiproliferative agents against various cancer cell lines (Berenyi 
et al., 2013; Szabo et al., 2016a). However, for example, 3-benzyl ether 
Fig. 3. A. Zombie Violet uptake in OATP2B1 and 
mock transfected cells. The histogram shows the up-
take of the Zombie Violet (ZV, 250x diluted) fluo-
rescent dye, a known substrate of OATP2B1 (Patik 
et al., 2018). A431 cells were incubated for 15 min at 
37 ◦C in uptake buffer (pH 5.5). Fluorescence was 
monitored by flow cytometry. Experiments were 
repeated every week in order to control OATP2B1 
expression. A representative histogram is shown. B. 
Expression of OATP2B1 in A431 cells confirmed by 
Western blot. OATP2B1 was detected by an anti- 
OATP2B1 antibody (Kullak-Ublick et al., 2001) and 
ß-actin was used as loading control. Experiments were 
repeated at least three times. One representative blot 
is shown.   
Fig. 4. Cell growth inhibition of compounds in A431 cells. A431 mock and A431-OATP2B1 cells were incubated with increasing steroid concentrations for 120 h on 
96-well plates. Cell number was determined based on the fluorescence of mCherry or GFP measured in an Enspire fluorescence plate reader, 100%: in the absence of 
estrones. Data show the mean ± SD values obtained from at least three independent measurements. 
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of the 16-oxime propionate in the 13α-estrone series was shown to be 
toxic not only to HeLa and MCF-7 cells, but also to A431 cells lacking the 
STS and HSD1 enzymes (Szabo et al., 2016a). In addition, triazolyl-13α- 
D-secoestrone derivatives exerted an excellent antiproliferative poten-
tial on human cervical (HeLa, C33), ovarian (A2780) and HR+ breast 
(MCF-7, T47D) cancer cell lines (Berenyi et al., 2013). 
Previously, we have shown that 13α- or 13β-estrone derivatives, 
originally designed to inhibit the STS and HSD1 enzymes, are effective 
inhibitors of OATP2B1 function (Jojart et al., 2018; Laczko-Rigo et al., 
2020; Jójárt et al., 2021). Hence, these estrones can be good candidate 
dual-targeted molecules simultaneously aiming a tumoric transporter as 
well as an enzyme. We hypothesized that if transported by OATP2B1 
these compounds can be enriched in and be more toxic to the cells 
overexpressing the transporter. Hence, we further investigated a set of 
these OATP2B1 inhibitor 13α-estrones (Fig. 2) and a recently identified 
OATP2B1 inhibitor with a nanomolar inhibitory constant, phospho-
nated 13β-estrone (1a_2P, Fig. 1) (Jójárt et al., 2021), for their ability to 
inhibit the proliferation of OATP2B1-overexpressing cells. For this aim, 
the A431 cell line, a well-established model for the investigation of 
OATP function (Windt et al., 2019) was applied. Although the toxicity of 
13α-estrones in A431 cells has not yet been investigated in detail, 
various 13α-estrones have been shown to be toxic in A431 cells (Szabo 
et al., 2016b). 
From the set of the investigated compounds, we found that 3-O- 
benzyl derivatives (2a, 2a_2P, 2a_4P, 1a_2P and 2a_4P) had increased 
Fig. 5. Effect of C-2 or C-4 diethylphosphonated 13α-estrone derivatives on the proliferation of A431 cells. A431 mock and A431-OATP2B1 cells were incubated with 
increasing steroid concentrations for 120 h. Cell number was determined based on mCherry or GFP fluorescence measured in an Enspire plate reader. Data show the 
mean values ± SD calculated from at least three independent measurements. 
Table 2 
Antiproliferative effect of the compounds on OATP2B1 and mock transfected 
cells.  
Name IC50 ± SD (μM) Name IC50 ± SD (μM) SR 
2B1 mock 2B1 mock 
1 42.01 36.36 2 >50 >50  
±0.033 ±0.029    
1a_2P 8.552 12.89 2_2P >50 >50  
±0.05 ±0.027    
2b >50 >50 2_4P >50 >50  
2b_2P 46.42 38.03 2_2I 15.78 36.57 2.32**** 
±0.022 ±0.028 ±0.051 ±0.016 
2b_4P 18.32 13.71 2_4I 27.76 28.48 1.03 
±0.036 ±0.036 ±0.022 ±0.167 
2a 10.36 14.65 2_2Br 32.4 129.8x 4.01**** 
±0.03 ±0.042 ±0.017 ±0.056 
2a_2P 15.91 17.45 2_4Br 77.52x 95.83x 1.24 
±0.03 ±0.039 ±0.051 ±0.084 
2a_4P 10.52 9.67 2_2Cl 23.92 51.21 2.14* 
±0.036 ±0.038 ±0.014 ±0.013    
2_4Cl 67.01 251.8x 3.75    
±0.024 ±0.037 
IC50 values were determined by nonlinear regression analysis fitted to the data 
points by GraphPad Prism software. SR = selectivity ratio: IC50 in mock/IC50 in 
OATP2B1, x: data were predicted by GraphPad Prism software. Statistically 
significant difference between IC50 values: *p < 0.05, ****p < 0.0001. Bold 
indicates compound names, italics is for SD values. 
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antiproliferative effect on A431 cells (their IC50 values below 20 μM) 
irrespective of the presence of OATP2B1. This harmonizes with our 
previous findings, various 13α-estrones with a C-3 N-benzyl-
triazolylmethoxy moiety being toxic on A431 cells (Szabo et al., 2016b). 
In the current study C-2 or C-4 iodinated 13α-estrones also resulted in a 
moderately increased antiproliferative effect (IC50 values around 30 μM) 
compared to the core 13α-estrone. While here only a limited set of 
compounds was investigated, since our study focused on the highest 
affinity inhibitors of OATP2B1 function, we observed that the intro-
duction of a large substituent on 3-hydroxy function of the initial 
compounds 13α- or 13β-estrone issued in enhanced cell growth inhibi-
tion effect. 
The OATP2B1-selective antiproliferative effect was observed exclu-
sively in the case of the 2-halogenated compounds. 2_2I, 2_2Br and 
2_2Cl resulted in a 2-, 4- and 2-fold decreased IC50 in A431-OATP2B1 
cells, respectively (Fig. 6 and Table 1). The C-4 halogenated counter-
parts were less effective inhibitors of OATP2B1 function, accordingly, 
they did not result in an OATP2B1-selective anti-proliferative effect. 
Furthermore, the OATP2B1-selective antiproliferative effect of 2_2Br 
could be inhibited by bromosulfophthalein (Supplementary Fig. S2A). In 
further experiments we demonstrated the OATP2B1-mediated uptake of 
the most selective compound 2_2Br (Fig. 8) that may explain its 
enhanced antiproliferative effect in OATP2B1-overexpressing cells. 
The 13α-estrones investigated here have been designed to inhibit the 
HSD1 enzyme (Bacsa et al., 2015; Jojart et al., 2018), and hence 
decrease the proliferation of hormone dependent tumors. A431 cells 
lack HSD1 and are hormone independent, however they are enriched in 
the 17ß-HSD type 2 (HSD2) enzyme (Blomquist et al., 1997). HSD2 has 
been shown to be inhibited by C18, C19 and C21 steroids (Blomquist 
et al., 1984), therefore, the investigated steroids may act through the 
inhibition of HSD2 in A431 cells. On the other hand, increased expres-
sion of estrogen-related receptor alpha (ERRα) has been documented in 
A431 cells (Chen et al., 2018). ERRα is an orphan nuclear receptor, of 
which upregulation is involved in the development of estrogen- 
independent tumors (Chen et al., 2018). Accordingly, suppression of 
ERRα inhibited A431 cell proliferation (Chen et al., 2018). However, 
whether the antiproliferative effect of 13α-estrones observed in our 
study can be related to the inhibition of the ERRα receptor needs further 
investigations. Interestingly, 2_2Br had only a slightly increased anti-
proliferative effect in estrogen-dependent T47D breast cancer cells (also 
expressing the HSD1 enzyme, Supplementary Fig. S2B) indicating that 
the compound may exert its antiproliferative effect independent of the 
estrogen pathway. Recently, 13α-estrones have been described as in-
hibitors of tubulin formation (Jojart et al., 2020), therefore this can be 
an alternative mechanism of cell growth inhibition in A431 cells. 
Many illnesses including cancer treatment require the simultaneous 
action on multiple targets in order to avoid drug resistance mechanisms, 
to increase effectiveness and to prolong overall survival. This is often 
achieved by drug “cocktails”. However, by the application of “cocktail 
therapy” the incidence of drug-drug interactions and off-target effects 
Fig. 6. Effect of C-2 or C-4 halogenated 13α-estrone derivatives on growth of A431 cells. A431 mock and A431-OATP2B1 cells were incubated with increasing steroid 
concentrations for 120 h on 96-well plates. Cell number was determined based on the fluorescence of mCherry or GFP in an Enpsire fluorescence plate reader. Data 
show the mean ± SD values obtained from at least three independent measurements. 
Fig. 7. Tritium labeling of 2_2Br. (i) Pd/C (10% Pd), 3H2, EtOAc, TEA; (ii) 1.2 equiv. DDH, CH2Cl2, 15 min, rt.  
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increases. Using a single chemical entity with multiple targets is a better 
strategy to avoid side effects (Meena et al., 2015). Multi-targeted drug 
design has not only been applied for anti-cancer treatment, but also for 
inflammatory conditions, Alzheimer’s disease and neurodegenerative 
disorders, as well (Geldenhuys and Van der Schyf, 2013). 
Here we identified 2-halogenated-13α-estrones as (potential) 
OATP2B1 substrates. Since these compounds are also effective HSD1 
inhibitors, their increased uptake mediated by OATP2B1 can potentially 
be exploited to achieve an enhanced anti-tumor effect in estrogen 
dependent tumors. Though further experiments on estrogen-dependent 
cell lines expressing the potential targets of 13α-estrones, the STS 
and/or HSD1 enzymes (e.g. T47D, MCF-7) with and without OATP2B1 
overexpression would be needed to clarify this issue. 
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